Literature DB >> 23173251

[Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet].

Shi-han Wang1, Jie Wang, Ji Li.   

Abstract

OBJECTIVE: To assess the clinical efficacy of danlou tablet (DT) in treating coronary heart disease angina (CHDA) patients of phlegm and stasis mutual obstruction syndrome (PSMOS).
METHODS: Totally 66 CHDA patients of PSMOS were recruited from four centers (Beijing Guang'anmen Hospital, Beijing Anzhen Hospital, First Affiliated Hospital of Henan College of Traditional Chinese Medicine, and Hubei Union Hospital). They were assigned to two groups according to the random digit table, the treatment group (treated by DT +Western medicine) and the control group (treated by Western medicine), 33 in each group. All patients took Western medicine. Patients in the treatment group were given DT, 1.5 g each time, twice daily, while those in the control group took DT placebo. The treatment course was 28 days for all. The efficacy of angina, the angina attack frequency, its duration, the score of angina, the numbers of ST segment depression and flat or inversed T wave, the lead number of inversed T wave, the angina relief time after taking nitroglycerin, the amount of nitroglycerin were observed in the two groups. The changes of Chinese medicine (CM) syndrome scores, including the duration and frequency of chest tightness and pain, shortness of breath, fatigue, palpitation, spontaneous sweating, and total syndrome score were compared before and after treatment. The changes of hypersensitive C-reactive protein (hs-CRP), homocysteic acid (HCY), soluble CD40 ligand (sCD40L), interleukin-6 (IL-6), myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9), and vascular cell adhesion molecular-1 (VCAM-1) were also observed in both groups.
RESULTS: The total effective rate was significantly higher in the treatment group (26/32 cases, 81.2%) when compared with the control group (13/30 cases, 43.3%, P < 0.05). Compared with before treatment in the same group, the duration and frequency of chest tightness and pain, the score of angina, the numbers of ST segment depression and flat or inversed T wave, the lead number of inversed T wave, the angina relief time after taking nitroglycerin, the amount of nitroglycerin, the duration and frequency of chest tightness and pain, hs-CRP, sCD40L, HCY, IL-6, MMP-9, MPO were lowered after treatment in both groups (P < 0.01, P < 0.05). The VCAM-1 level decreased in the treatment group, while it increased in the control group, showing statistical difference (P < 0.01, P < 0.05). Compared with the control group after treatment, the duration and frequency of chest tightness and pain, the score of angina, the angina relief time after taking nitroglycerin, the amount of nitroglycerin, the duration and frequency of chest tightness and pain, fatigue, the total syndrome score, the levels of hs-CRP, sCD40L, HCY, IL-6, MMP-9, MPO, and VCAM-1 were lowered in the treatment group after treatment (P < 0.01, P < 0.05).
CONCLUSION: DT could improve CHDA patients' clinical symptoms, inhibit the inflammation reaction, showing plaque stabilizing and anti-oxidization effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23173251

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  7 in total

1.  Effect of Danlou Tablet () on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial.

Authors:  Lei Wang; Shuai Mao; Jian-yong Qi; Yi Ren; Xin-feng Guo; Ke-ji Chen; Min-zhou Zhang
Journal:  Chin J Integr Med       Date:  2015-07-04       Impact factor: 1.978

2.  Protective Effects of Danlou Tablet () against Murine Myocardial Ischemia and Reperfusion Injury In Vivo.

Authors:  Jian-Yong Qi; Lei Wang; Dong-Sheng Gu; Li-Heng Guo; Wei Zhu; Min-Zhou Zhang
Journal:  Chin J Integr Med       Date:  2016-03-21       Impact factor: 1.978

3.  The anti-inflammatory activities of ethanol extract from Dan-Lou prescription in vivo and in vitro.

Authors:  Li-Na Gao; Xin Zhou; Yi Zhang; Yuan-Lu Cui; Chun-Quan Yu; Shan Gao
Journal:  BMC Complement Altern Med       Date:  2015-09-09       Impact factor: 3.659

4.  Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study.

Authors:  Shuai Mao; Lei Wang; Wenwei Ouyang; Yuanshen Zhou; Jianyong Qi; Liheng Guo; Minzhou Zhang; Aleksander Hinek
Journal:  BMC Complement Altern Med       Date:  2016-11-08       Impact factor: 3.659

5.  Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial.

Authors:  Lei Wang; Xujie Zhao; Shuai Mao; Shaonan Liu; Xinfeng Guo; Liheng Guo; Tinghai Du; Haiyu Yang; Fuhai Zhao; Keng Wu; Hongliang Cong; Yang Wu; Phillip C Yang; Keji Chen; Minzhou Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-08       Impact factor: 2.629

6.  Integrated Modules Analysis to Explore the Molecular Mechanisms of Phlegm-Stasis Cementation Syndrome with Ischemic Heart Disease.

Authors:  Wei-Ming Xu; Kuo Yang; Li-Jie Jiang; Jing-Qing Hu; Xue-Zhong Zhou
Journal:  Front Physiol       Date:  2018-01-22       Impact factor: 4.566

7.  Traditional Chinese Medicine for Coronary Heart Disease: Clinical Evidence and Possible Mechanisms.

Authors:  Ke-Jian Zhang; Qun Zheng; Peng-Chong Zhu; Qiang Tong; Zhuang Zhuang; Jia-Zhen Zhu; Xiao-Yi Bao; Yue-Yue Huang; Guo-Qing Zheng; Yan Wang
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.